A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of palifermin (recombinant
human keratinocyte growth factor, rHuKGF) in reducing the incidence of severe oral mucositis
in subjects with locally advanced head and neck cancer receiving radiotherapy with concurrent
chemotherapy as adjuvant treatment for their disease.